Polymer-protein-enhanced fluoroimmunoassay for prostate-specific antigen

Analytical and Bioanalytical Chemistry

Volumn 396, Issue 2, 2010, Pages 681-686

  MacKness, Brian C ^a   Chourb, Sinang ^a   Farris, Leslie R ^a   McDonald, Melisenda J ^a  

^a University of Massachusetts Lowell   (United States)

Author keywords

ALYGNSA; Cancer biomarker; ELISA; Free to total PSA ratio; Immunoassay; Prostate specific antigen (PSA)

Indexed keywords

CANCER BIOMARKERS; DETECTION LIMITS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ASSAYS; FLUOROIMMUNOASSAYS; LIMITS OF DETECTION; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN;

ANTIGENS; IMMUNOLOGY; TRACE ANALYSIS;

PEELING;

POLYMER; PROSTATE SPECIFIC ANTIGEN;

BLOOD; CHEMISTRY; CONFERENCE PAPER; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FLUOROIMMUNOASSAY; HUMAN; MALE; METHODOLOGY; PROSTATE TUMOR; STATISTICAL PARAMETERS;

ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUOROIMMUNOASSAY; HUMANS; LIMIT OF DETECTION; MALE; POLYMERS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 76849087992     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-009-3234-6     Document Type: Conference Paper

References (16)

1. American Cancer Society (2009) Cancer facts & figures 2009. American Cancer Society, Atlanta
2. EI Canto KM Slawin 2002 Early management of prostate cancer: how to respond to an elevated PSA? Annu Rev Med 53 355 368 10.1146/annurev.med.53. 082901.104000 1:CAS:528:DC%2BD38Xitl2mt78%3D (Pubitemid 34177886)
3. SP Balk YJ Ko GJ Bubley 2003 Biology of prostate-specific antigen J Clin Oncol 21 383 391 10.1200/JCO.2003.02.083 1:CAS:528:DC%2BD2cXpsVWqs7c%3D (Pubitemid 46606169)
4. S Loeb W Catalona 2008 What to do with an abnormal PSA test Oncologist 13 299 305 10.1634/theoncologist.2007-0139 1:CAS:528:DC%2BD1cXltlChsrg%3D (Pubitemid 351679905)
5. RA Smith V Cokkinides HJ Eyre 2006 American cancer society guidelines for the early detection of cancer CA Cancer J Clin 56 11 25 10.3322/canjclin.56.1. 11
6. X Filella D Truan J Alcover L Quinto R Molina P Luque F Coca A Ballesta 2004 Comparison of several combinations of free, complexed and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms Urology 63 1100 1104 10.1016/j.urology.2004.01.056 (Pubitemid 38746811)
7. RJ Sotelo KE Mora LH Pérez J Novoa O Carmona R De Andrade RE Borges D Parada S Loeb WJ Catalona 2007 Assay standardization bias: different prostate cancer detection rates and clinical outcomes resulting from different assays for free and total prostate-specific antigen Urology 69 1143 1146 10.1016/j.urology.2007.02.006 (Pubitemid 46891573)
8. WJ Catalona AW Partin KM Slawin MK Brawer RC Flanigan A Patel JP Richie JB deKernion PC Walsh PT Scardino PH Lange ENP Subong RE Parson GH Gasior KG Loveland PC Southwick 1998 Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial JAMA 279 1542 1547 10.1001/jama.279.19.1542 1:STN:280:DyaK1c3ms12gtw%3D%3D (Pubitemid 28233009)
9. M Saraiya BJ Kottiri S Leadbetter D Blackman T Thompson MT McKenna FL Stallings 2005 Total and percent free prostate-specific antigen levels among U.S. men, 2001-2002 Cancer Epidemiol Biomarkers Prev 14 2178 2182 10.1158/1055-9965.EPI-05-0206 1:CAS:528:DC%2BD2MXhtVWgtbrI (Pubitemid 41603265)
10. Y Baumgart A Otto A Schafer E Usbeck C Cott A Schott M Tornack A Wenzel A Mossie G Birkenmeier 2005 Characterization of novel monoclonal antibodies for prostate-specific antigen (PSA) with potency to recognize PSA bound to α 2-macroglobulin Clin Chem 51 84 92 10.1373/clinchem.2004.039636 1:CAS:528:DC%2BD2MXlt1ynsQ%3D%3D (Pubitemid 40024016)
11. J Leinonen P Niemelä J Lövgren L Bocchi K Pettersson H Nevanlinna U Stenman 2004 Characterization of monoclonal antibodies against prostate specific antigen produced by genetic immunization J Immunol Methods 289 157 167 10.1016/j.jim.2004.04.022 1:CAS:528:DC%2BD2cXlsFOru70%3D (Pubitemid 38900913)
12. LJ Clarizia D Sok M Wei J Mead C Barry MJ McDonald 2009 Antibody orientation enhanced by selective polymer-protein noncovalent interactions Anal Bioanal Chem 393 1531 1538 10.1007/s00216-008-2567-x 1:CAS:528: DC%2BD1cXhsFans73J
13. D Sok LJ Clarizia LR Farris MJ McDonald 2009 Novel fluoroimmunoassay for ovarian cancer biomarker CA-125 Anal Bioanal Chem 393 1521 1523 10.1007/s00216-008-2569-8 1:CAS:528:DC%2BD1MXlvFymug%3D%3D
14. Crowther JR (1995) The ELISA guidebook. Humana, New Jersey, pp 9-44
15. JW Lee M Hall 2009 Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis J Chromatogr 877 1259 1271 10.1016/j.jchromb.2008.11.022 1:CAS:528:DC%2BD1MXksVCrsrg%3D
16. M Paliouras C Borgono EP Diamandis 2007 Human tissue kallikreins: the cancer biomarker family Cancer Lett 249 61 79 10.1016/j.canlet.2006.12.018 1:CAS:528:DC%2BD2sXjsVektL4%3D (Pubitemid 46427999)